Latest News and Press Releases

Allure Magazine Honors Arcutis’ ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award

WESTLAKE VILLAGE, Calif., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations...

Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children

Arcutis today announced that management will participate in three upcoming investor conferences.

WESTLAKE VILLAGE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

Arcutis today reported financial results for the quarter ended June 30, 2025, and provided a business update.

Arcutis announced today that it will report Q2 2025 financial results and provide a business update on Aug 6, 2025 after the U.S. financial markets close.

WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in...

The American Academy of Dermatology (AAD) provided evidence-based recommendation for the use of ZORYVE® (roflumilast) cream 0.15% in adults with AD

The first child has been enrolled in Phase 2 INTEGUMENT-INFANT study evaluating the safety and tolerability of investigational ZORYVE cream for AD